All In Biotech

Drug Trial Radar · NCT02189629

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 (Trifarotene) 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS

Last checked: Nov 19, 2026Latest source record: Nov 14, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

453

Actual

Start

Feb 23, 2015

Primary completion

Feb 23, 2017

Study completion Feb 23, 2017

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jul 14, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 9 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • CD5789 (trifarotene)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator Global Assessment (IGA) Success Rate up to Week 52Time frame: From Baseline to Week 52

Locations

32 sites in 4 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site

    Mobile, Alabama

  • Galderma Investigational Site

    Rogers, Arkansas

  • Galderma Investigational Site

    Sacramento, California

  • Galderma Investigational Site

    San Diego, California

  • Galderma Investigational Site

    Miami, Florida

  • Galderma Investigational Site

    Miramar, Florida

  • Galderma Investigational Site

    Newnan, Georgia

  • Galderma Investigational Site

    Louisville, Kentucky

  • Galderma Investigational Site

    Albuquerque, New Mexico

  • Galderma Investigational Site

    New York, New York

  • Galderma Investigational Site

    High Point, North Carolina

  • Galderma Investigational Site

    Beachwood, Ohio

  • Galderma Investigational Site

    Portland, Oregon

  • Galderma Investigational Site

    Knoxville, Tennessee

  • Galderma Investigational Site

    Chomutov, Czechia

  • Galderma Investigational site

    Hradec Králové, Czechia

  • Galderma Investigational Site

    Olomouc, Czechia

  • Galderma Investigational Site

    Pardubice, Czechia

  • Galderma Investigational site

    Prague, Czechia

  • Galderma Investigational Site

    Augsburg, Germany

  • Galderma Investigational Site

    Berlin, Germany

  • Galderma Investigational Site

    Berlin, Germany

  • Galderma Investigational Site

    Dessau, Germany

  • Galderma Investigational Site

    Mahlow, Germany

  • Galderma Investigational Site

    Münster, Germany

  • Galderma Investigational Site

    Wuppertal, Germany

  • Galderma Investigational Site

    Balatonfüred, Hungary

  • Galderma Investigational Site

    Miskolc, Hungary

  • Galderma Investigational Site

    Pécel, Hungary

  • Galderma Investigational Site

    Szeged, Hungary

  • Galderma Investigational Site

    Szekszárd, Hungary

  • Galderma Investigational Site

    Szolnok, Hungary

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.